Los Angeles Capital Management LLC Buys Shares of 93,417 Travere Therapeutics, Inc. (NASDAQ:TVTX)

Los Angeles Capital Management LLC purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the 1st quarter, Holdings Channel reports. The fund purchased 93,417 shares of the company’s stock, valued at approximately $720,000.

Other large investors have also modified their holdings of the company. Signaturefd LLC boosted its stake in Travere Therapeutics by 1,656.4% during the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after purchasing an additional 2,849 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Travere Therapeutics by 968.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after buying an additional 5,121 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Travere Therapeutics by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock worth $78,000 after buying an additional 6,773 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Travere Therapeutics in the 4th quarter worth approximately $137,000. Finally, Virtu Financial LLC acquired a new stake in Travere Therapeutics in the 4th quarter valued at approximately $175,000.

Travere Therapeutics Stock Up 6.6 %

Shares of NASDAQ:TVTX opened at $7.79 on Tuesday. The company has a debt-to-equity ratio of 5.10, a quick ratio of 2.75 and a current ratio of 2.78. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $17.57. The company has a 50 day moving average price of $6.59 and a 200 day moving average price of $7.72.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.78). The company had revenue of $41.40 million for the quarter, compared to the consensus estimate of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The business’s revenue was up 34.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.27) earnings per share. As a group, equities analysts forecast that Travere Therapeutics, Inc. will post -3.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TVTX shares. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Guggenheim reaffirmed a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Travere Therapeutics in a research note on Tuesday, May 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.58.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.